Related Experiment Video
Updated: Jan 29, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve
Zarchi E Sumon1, Charles S Berenson1,2, John A Sellick1,2
1a Department of Medicine, Infectious Diseases Division , University at Buffalo, Jacobs School of Medicine and Biomedical Sciences , Buffalo , NY , USA.
Abstract:
Infectious complications following surgical valve replacements are extremely difficult to treat, often requiring prolonged antimicrobials therapy with or without surgery. Vancomycin-intermediate Staphylococcus aureus is an infrequent pathogen, with an estimated prevalence of less than 0.3%, but presents even greater challenges. We report a case of successful cure of daptomycin-non-susceptible and vancomycin-intermediate Staphylococcus aureus prosthetic valve endocarditis using an eight-week course of combination antimicrobial therapy. Using time-kill study, the combination of daptomycin plus ceftaroline and rifampin resulted in a greater than 4 log reduction of bacterial growth at 24 hours. This antimicrobial combination was used for a total of eight weeks with a successful outcome.
Insights
This study details a successful treatment for a rare Staphylococcus aureus prosthetic valve endocarditis. A combination therapy of daptomycin, ceftaroline, and rifampin cured the infection in eight weeks.
Area of Science:
- Infectious Diseases
- Antimicrobial Resistance
- Cardiovascular Surgery
Background:
- Infectious complications after surgical valve replacement are challenging to manage, often necessitating prolonged antimicrobial therapy or reoperation.
- Vancomycin-intermediate Staphylococcus aureus (VISA) is an uncommon pathogen, accounting for less than 0.3% of cases, posing significant treatment difficulties.
- Prosthetic valve endocarditis (PVE) caused by drug-resistant bacteria represents a critical clinical scenario.
Observation:
- A case of PVE caused by daptomycin-non-susceptible and vancomycin-intermediate Staphylococcus aureus was encountered.
- Standard treatment options were limited due to the specific resistance profile of the pathogen.
- The patient presented with a complex infectious endocarditis requiring innovative therapeutic strategies.
Findings:
- A combination antimicrobial regimen including daptomycin, ceftaroline, and rifampin was administered.
- In vitro time-kill studies demonstrated synergistic activity, achieving a >4 log reduction in bacterial growth within 24 hours.
- The eight-week course of this combination therapy resulted in a successful clinical outcome, eradicating the infection.
Implications:
- This case highlights a potential effective treatment strategy for challenging PVE cases involving multidrug-resistant Staphylococcus aureus.
- Combination therapy may overcome resistance mechanisms and improve outcomes in severe prosthetic valve endocarditis.
- Further research into novel antimicrobial combinations is warranted for treating resistant bacterial infections in cardiovascular surgery.
More Related Videos
Related Concept Videos
Ecological Succession
Curing of Concrete
Curing Methods
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis I: Introduction
Accelerated Curing of Concrete

